Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1618 1643 1647 1681 1682 1797
This examiner grants 81% of resolved cases
Robert S Landsman has a volume of 1276 resolved cases in Tech Center 1700 and Art Unit 1618. His allowance rate pct is 81.3, and the median days to allowance is 796. These figures suggest the probability of success and the prosecution process. The 796-day median to allowance is a benchmark for applicants in Art Unit 1618 and can be used to estimate the time to grant.
The interview lift pct of 13.0 indicates that interviews are a way to secure an allowance. This 13.0 lift suggests that direct engagement can further improve the 81.3 allowance rate pct. With 1276 resolved cases, the data reflects the documented examiner profile. The 13.0 lift is a metric that practitioners should consider when deciding whether to request an interview to resolve outstanding issues and maintain the 81.3 allowance rate pct.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18613945 | USE OF APPROVED BISPECIFIC EGFR AND MET SPECIFIC ANTIBODY DRUG PRODUCT TO TREAT NON-SMALL CELL LUNG CANCER | Non-Final OA | Janssen Biotech, Inc. |
| 18481673 | RECOMBINANT LIGASE COMPOSITION AND USES THEREOF | Non-Final OA | 10x Genomics, Inc. |
| 18561673 | JAK Inhibitors for Managing Conditions in Patients with Down's Syndrome or Other Trisomy | Non-Final OA | Emory University |
| 18482223 | HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18682707 | COMPOSITIONS AND METHODS FOR ENHANCING BRAIN PERFUSION | Non-Final OA | Washington University |
| 18289674 | SINGLE CHAIN TRIMER MHC CLASS I NUCLEIC ACIDS AND PROTEINS AND METHODS OF USE | Non-Final OA | California Institute of Technology |
| 18489525 | METHODS FOR PREVENTING AND TREATING HEART DISEASE | Final Rejection | Beth Israel Deaconess Medical Center, Inc. |
| 18544247 | GENE THERAPY TREATMENT OF ATRIAL FIBRILLATION | Non-Final OA | Northwestern University |
| 18595973 | ANTI-HLA-DQ2.5/8 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18289627 | ANTI-DDR2 ANTIBODIES AND USES THEREOF | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18702227 | FC VARIANTS HAVING IMPROVED PH-DEPENDENT FCRN BINDING CAPACITY AND FCRIIIA BINDING SELECTIVITY | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18579526 | IDENTIFICATION OF COMMON TUMOR-SPECIFIC T CELL RECEPTORS AND ANTIGENS | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 18287556 | CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS | Non-Final OA | Imperial College Innovations Limited |
| 18287542 | CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS | Non-Final OA | Imperial College Innovations Limited |
| 18555214 | METHODS TO DETERMINE TREATMENT EFFICACY WITH GAMMA-DELTA T CELLS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18245257 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | Final Rejection | St. Jude Children's Research Hospital, Inc. |
| 18691384 | AMINOPEPTIDASE N-SPECIFIC MONOCLONAL ANTIBODIES AND USES THEREOF | Non-Final OA | Universiteit Gent |
| 18682713 | CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING gD AND ONCOLYTIC VIRUSES FOR CANCER THERAPY AND TREATMENT OF HSV | Non-Final OA | City of Hope |
| 18282919 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18615679 | CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR USE IN THE TREATMENT AND PREVENTION OF RHEUMATOID ARTHRITIS | Non-Final OA | Viela Bio, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy